← Back to headlines
A16z-Backed Biotech Braveheart Seeks $318.8 Million in US IPO
Braveheart Bio Inc., a clinical-stage biopharmaceutical company supported by a16z, is aiming to raise up to $318.8 million in an initial public offering in the US.
30 Jul, 12:02 — 30 Jul, 12:02
